Skip to main content
    S

    Sionna Therapeutics, Inc. Common Stock (SION)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.12
    -0.21 (-6.31%)

    Market Cap: $150.63M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Sionna Therapeutics, Inc. Common Stock (SION) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Sionna Therapeutics, Inc. Common Stock are Sutro Biopharma (STRO), LENZ Therapeutics (LENZ) and NeOnc Technologies Holdings, Inc. Common Stock (NTHI). By market cap, Sionna Therapeutics, Inc. Common Stock ranks 7th of the 13 companies on this page; Bright Minds Biosciences (DRUG) is the largest at $227.96M.

    Peer Comparison

    SION's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Sionna Therapeutics, Inc. Common Stock (SION)$150.63MN/AN/A0.0%N/A0.0%0.00%
    Sutro Biopharma (STRO)$163.03MN/A3.4x0.0%N/A-6.1%0.00%
    LENZ Therapeutics Inc (LENZ)$129.77MN/A9.7x0.0%N/A-72.9%0.00%
    NeOnc Technologies Holdings, Inc. Common Stock (NTHI)$141.66MN/AN/A0.0%N/A-100.0%0.00%
    Cassava Sciences Inc (SAVA)$114.97MN/AN/A0.0%N/A0.0%0.00%
    Minerva Neurosciences Inc (NERV)$114.62MN/AN/A0.0%N/A0.0%0.00%
    Innate Pharma (IPHA)$154.15MN/A17.6x0.0%489.8%16.5%0.00%
    Eledon Pharmaceuticals Inc (ELDN)$178.63MN/AN/A0.0%N/A0.0%0.00%
    Neumora Therapeutics, Inc. (NMRA)$80.59MN/AN/A0.0%-260.5%0.0%0.00%
    Invivyd Inc. (IVVD)$171.58MN/A2.9x-183.9%N/A21.2%0.00%
    Bright Minds Biosciences Inc (DRUG)$227.96MN/AN/A0.0%-11.2%0.0%0.00%
    NRX Pharmaceuticals Inc (NRXP)$95.58MN/A23.8x0.0%N/A0.0%0.00%
    Inhibikase Therapeutics Inc (IKT)$213.21MN/AN/A0.0%N/A-100.0%0.00%
    Peer median$147.90MN/A9.7x0.0%-11.2%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Sionna Therapeutics, Inc. Common Stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Sutro Biopharma (STRO)
    Sutro Biopharma, Inc. is a clinical stage drug discovery, development and manufacturing company.
    STRO competitors
    LENZ Therapeutics Inc (LENZ)
    LENZ Therapeutics Inc is a cutting-edge biopharmaceutical company dedicated to developing transformative therapies for neurological disorders...
    LENZ competitors
    NeOnc Technologies Holdings, Inc. Common Stock (NTHI)
    NeOnc Technologies Holdings, Inc. is a pioneering biotechnology firm dedicated to revolutionizing cancer treatment through its advanced immunotherapy...
    NTHI competitors
    Cassava Sciences Inc (SAVA)
    Cassava Sciences, Inc., a clinical-stage biotechnology company, develops drugs for neurodegenerative diseases. The company is headquartered in Austin, Texas.
    Minerva Neurosciences Inc (NERV)
    Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of candidate products...
    NERV competitors
    Innate Pharma (IPHA)
    Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France...
    Eledon Pharmaceuticals Inc (ELDN)
    Eledon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing drugs for patients living with autoimmune diseases...
    ELDN competitors
    Neumora Therapeutics, Inc. (NMRA)
    Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases...
    NMRA competitors
    Invivyd Inc. (IVVD)
    Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery...
    IVVD competitors
    Bright Minds Biosciences Inc (DRUG)
    Bright Minds Biosciences Inc. (DRUG) is a forward-thinking clinical-stage biotechnology firm specializing in the development of groundbreaking therapies...
    DRUG competitors
    NRX Pharmaceuticals Inc (NRXP)
    NRx Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company...
    NRXP competitors
    Inhibikase Therapeutics Inc (IKT)
    Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside...
    IKT competitors

    Frequently Asked Questions About SION

    Who are Sionna Therapeutics, Inc. Common Stock's main competitors?

    The companies most similar to Sionna Therapeutics, Inc. Common Stock include Sutro Biopharma (STRO), LENZ Therapeutics (LENZ), NeOnc Technologies Holdings, Inc. Common Stock (NTHI), Cassava Sciences (SAVA) and Minerva Neurosciences (NERV), listed from the closest match.

    Who is Sionna Therapeutics, Inc. Common Stock's biggest competitor?

    Bright Minds Biosciences (DRUG) is the largest of the similar companies at $227.96M; Sutro Biopharma (STRO) is the closest match by business profile, size, sector and industry.

    How does SION stock compare with its competitors?

    SION's net margin is 0.0% against a peer median of 0.0%.

    Which of Sionna Therapeutics, Inc. Common Stock's competitors pays a higher dividend?

    Sionna Therapeutics, Inc. Common Stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Sionna Therapeutics, Inc. Common Stock bigger than its competitors?

    No. Sionna Therapeutics, Inc. Common Stock is 7th by market cap among the 13 companies on this page; the largest is Bright Minds Biosciences (DRUG) at $227.96M.